Ligand Enters OmniAb® License Agreement with TeneoBio, Inc.

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide license agreement with Menlo Park, CA-based TeneoBio, Inc. Under the license, TeneoBio will be able to use the OmniFlic®technology from the OmniAb® platform to discover fully human bispecific antibodies to be developed for the treatment of various diseases, with an initial focus on therapeutics for cancer, autoimmunity, and infectious diseases.
Read more